國家衛生研究院 NHRI:Item 3990099045/14152
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 909160      在线人数 : 830
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14152


    题名: Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients
    作者: Blanchard, P;Lee, AWM;Carmel, A;Wai Tong, N;Ma, J;Chan, ATC;Hong, RL;Chen, MY;Chen, L;Li, WF;Huang, PY;Kwong, DLW;Poh, SSX;Ngan, R;Mai, HQ;Ollivier, C;Fountzilas, G;Zhang, L;Bourhis, J;Aupérin, A;Lacas, B;Pignon, JP;Benhamou, E;Chakrabandhu, S;Tc Chan, A;Chen, QY;Chen, Y;Chappell, RJ;Choi, H;Tt Chua, D;Lee Kiang Chua, M;Higgins, J;Hong, MH;Hong, RL;Pun Hui, E;Hsiao, CF;Kam, M;Angeliki Koliou, G;Lw Kwong, D;Lai, SC;On Lam, K;LeBlanc, ML;Wm Lee, A;Fun Victor Lee, H;Fei Li, W;Ma, B;Mo, F;Moon, J;Tong Ng, W;O'Sullivan, B;Petit, C;Pierre Pignon, J;Poh, SX;Rücker, G;Sham, J;Lim Soong, Y;Sun, Y;Tan, T;Tang, LQ;Tung, Y;Wee, J;Wu, X;Xu, T;Zhang, Y;Zhu, G;on behalf of the MACNPCcG
    贡献者: Institute of Population Health Sciences
    摘要: Purpose: Chemotherapy, when added to radiotherapy, improves survival in locally advanced nasopharyngeal carcinoma (NPC). This article presents the second update of the Meta-Analysis of Chemotherapy in NPC. Methods: Published or unpublished randomized trials assessing radiotherapy (±a second chemotherapy timing) with/without chemotherapy in non-metastatic NPC patients were identified. Updated data were sought for studies included in the previous rounds of the meta-analysis. The primary endpoint was overall survival. All trials were analyzed following the intent-to-treat principle using a fixed-effects model. Treatments were classified in five subsets according to chemotherapy timing. The statistical analysis plan was pre-specified. Results: Eighteen new trials were identified. Individual patient data were available for seven. In total, the meta-analysis now included 26 trials and 7,080 patients. The addition of chemotherapy reduced the risk of death, with a hazard ratio (HR) of 0.79 (95% confidence interval (CI) [0.73; 0.85]), and an absolute survival increase at 5 and 10 years of 6.1% [+3.9; +8.3] and + 8.4% [+5.7; +11.1], respectively. The largest effect was observed for concomitant + adjuvant, induction (with concomitant in both arms) and concomitant chemotherapy, with respective HR [95%CI] of 0.68 [0.59; 0.79] (absolute survival increase at 5 years: 12.3% (7.0%;17.6%)), 0.73 [0.63; 0.86] (6.0% (2.5%;9.5%)) and 0.81 [0.70; 0.92] (5.2% (0.8%;9.6%)). The benefit of chemotherapy was also demonstrated by improvement in progression-free survival, cancer mortality, locoregional control and distant control. There was a significant interaction between patient age and chemotherapy effect. Conclusion: This updated meta-analysis confirms the benefit of concomitant chemotherapy and concomitant + adjuvant chemotherapy, and suggests that addition of induction or adjuvant chemotherapy to concomitant chemotherapy improves tumor control and survival. The benefit of chemotherapy decreases with increasing patient age.
    日期: 2022-01
    關聯: Clinical and Translational Radiation Oncology. 2022 Jan;32:59-68.
    Link to: http://dx.doi.org/10.1016/j.ctro.2021.11.007
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2405-6308&DestApp=IC2JCR
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85124746344
    显示于类别:[Chin-Fu Hsiao] Periodical Articles

    文件中的档案:

    档案 描述 大小格式浏览次数
    SCP85124746344.pdf2244KbAdobe PDF171检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈